Alembic Pharma gets USFDA nod to market drug to treat cholestoral levels

VADODARA (BARODA) | MUMBAI | AHMEDABAD-GANDHINAGAR-RAJKOT – In a regulatory filing submitted to the Indian Stock Exchanges, Vadodara (Baroda) headquartered Indian pharma major, Alembic Pharmaceuticals Ltd said of having got nod from US FDA (Food & Drugs Administration) to market drug to treat cholesterol related disorders.

The press-statement titled, “Alembic Pharmaceuticals receives USFDA Approval for Fenofibrate Tablets USP, 48 mg and 145 mg.,” as submitted to the Indian Bourses, read that, Alembic Pharmaceuticals Limited today announced that the Company has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Fenofibrate Tablets USP, 48 mg and 145 mg.

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Tricor Tablets, 48 mg and 145 mg, of AbbVie Inc. (AbbVie).

Fenofibrate Tablets, USP are indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), Triglycerides and apolipoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDLC) in adult patients with primary hypercholesterolernia or mixed dyslipidemia.

It is also indicated as adjunctive therapy to diet for treatment of adult patients with severe hypertriglyceridemia.

Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacologic intervention.

Markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dL) may increase the risk of developing pancreatitis.

The effect of fenofibrate therapy on reducing this risk has not been adequately studied.

Fenofibrate Tablets USP, 48 mg and 145 mg have an estimated market size of US$ 94 million for twelve months ending December 2018 according to IQVIA.

Alembic now has a total of 102 ANDA approvals (90 final approvals and 12 tentative approvals) from USFDA.


FacebookGoogle+LinkedinTwitterYouTube, Blogspot, Telegram, Instagram 


Do NOT follow this link or you will be banned from the site!